摘要
目的观察布地奈德福莫特罗粉吸入剂治疗咳嗽变异性哮喘(CVA)患者的疗效及对肺功能、小气道功能的影响,为临床诊疗提供依据。方法选取2018年3月-2020年3月温州医科大学附属衢州医院/衢州市人民医院收治的CVA患者160例为研究对象,采用随机数字表法分为观察组和对照组,各80例。对照组采用孟鲁司特钠治疗,观察组在对照组基础上联合布地奈德福莫特罗吸入剂治疗。比较2组治疗效果,治疗前后肺功能、小气道功能变化,以及不良反应发生情况。结果治疗8周,观察组总有效率为95.00%,高于对照组的85.00%(χ^(2)=4.444,P=0.035);治疗8周后,2组用力肺活量(FVC)较治疗前增大、第1秒用力呼气容积(FEV1)较治疗前升高(P均<0.01),且观察组FVC、FEV1高于对照组(P均<0.01);治疗8周后,2组剩余75%用力肺活量时的呼气流速(MEF75%)、剩余50%用力肺活量时的呼气流速(MEF50%)、剩余25%用力肺活量时的呼气流速(MEF25%)均较治疗前升高(P<0.05或P<0.01),且观察组各项指标高于对照组,差异有统计学意义(P<0.05或P<0.01);2组不良反应发生率比较差异无统计学意义(χ^(2)=0.526,P=0.468)。结论在孟鲁司特钠治疗基础上联合应用布地奈德福莫特罗粉吸入剂治疗CVA患者的疗效明显,可有效改善患者肺功能、小气道功能,安全性高,值得临床推广应用。
Objective To explore the efficacy of budesonide formoterol powder inhalation in the treatment of patients with cough variant asthma(CVA)and its effect on lung function and small airway function,so as to provide basis for clinical diagnosis and treatment.Methods A total of 160 CVA patients admitted to the Quzhou Hospital Affiliated of Wenzhou Medical University/Quzhou People's Hospital from March 2018 to March 2020 were selected as the research objects,and were divided into observation group and control group by random number table method,with 80 cases in each group.The control group was treated with montelukast sodium,and the observation group was treated with budesonide formoterol powder inhalation on this basis.After 8 weeks of treatment,the effects of the two groups were compared,the changes in lung function and small airway function before and after treatment were recorded,and adverse reactions were counted.Results After 8 weeks of treatment,the total effective rate of the observation group was 95.00%,which was higher than 85.00%of the control group,the difference was statistically significant(χ^(2)=4.444,P=0.035).After 8 weeks of treatment,the forced vital capacity(FVC)in the two groups increased compared with before treatment,and the forced expiratory volume in the first second(FEV1)increased compared with before treatment(P<0.01),and the observation group FVC,FEV1 higher than the control group(P all<0.01).After 8 weeks of treatment,the expiratory flow rate at the remaining 75%forced vital capacity(MEF75%),the expiratory flow rate at the remaining 50%forced vital capacity(MEF50%),and the expiratory flow rate at the remaining 25%forced vital capacity(MEF25%)were all higher than before treatment(P<0.05 or P<0.01),and various indicators of the observation group were higher than those of the control group(P<0.05 or P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(χ^(2)=0.526,P=0.468).Conclusion Budesonide formoterol powder inhalation has an obvious curative effect in the treatment of CVA,which can effectively improve the lung function and small airway function of patients with high safety and is worthy of popularization.
作者
雷颖
LEI Ying(Department of Respiratory and Critical Care Medicine,the Quzhou Hospital Affiliated of Wenzhou Medical University/Quzhou People's Hospital,Zhejiang Province,Quzhou 324000,China)
出处
《临床合理用药杂志》
2021年第26期1-3,7,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
咳嗽变异性哮喘
布地奈德福莫特罗粉吸入剂
肺功能
小气道功能
临床疗效
不良反应
Cough variant asthma
Budesonide formoterol powder inhalation
Lung function
Small airway function
Clinical efficacy
Adverse reactions
